Beclin-1-mediated activation of autophagy improves proximal and distal urea cycle disorders.

Urea cycle disorders (UCD) are inherited defects in clearance of waste nitrogen with high morbidity and mortality. Novel and more effective therapies for UCD are needed. Studies in mice with constitutive activation of autophagy unraveled Beclin-1 as druggable candidate for therapy of hyperammonemia. Next, we investigated efficacy of cell penetrating autophagy inducing Tat-Beclin-1 (TB-1) peptide for therapy of the two most common UCD, namely ornithine transcarbamylase (OTC) and argininosuccinate lyase (ASL) deficiencies. TB-1 reduced urinary orotic acid and hyperammonemia, and improved survival under protein-rich diet in spf-ash mice, a model of OTC deficiency (proximal UCD). In Asl Neo/Neo mice, a model of ASL deficiency (distal UCD), TB-1 increased ureagenesis, reduced argininosuccinate, and improved survival. Moreover, it alleviated hepatocellular injury and decreased both cytoplasmic and nuclear glycogen accumulation in Asl Neo/Neo mice. In conclusion, Beclin-1-dependent activation of autophagy improved biochemical and clinical phenotypes of proximal and distal defects of the urea cycle.

[1]  L. Galluzzi,et al.  Autophagy in hepatic adaptation to stress. , 2020, Journal of hepatology.

[2]  P. Gissen,et al.  Urea Cycle Related Amino Acids Measured in Dried Bloodspots Enable Long-Term In Vivo Monitoring and Therapeutic Adjustment , 2019, Metabolites.

[3]  N. Brunetti‐Pierri,et al.  Ammonia and autophagy: An emerging relationship with implications for disorders with hyperammonemia , 2019, Journal of inherited metabolic disease.

[4]  Matthew S. Gentry,et al.  Nuclear Glycogenolysis Modulates Histone Acetylation in Human Non-Small Cell Lung Cancers. , 2019, Cell metabolism.

[5]  A. Erez,et al.  Argininosuccinic aciduria: Recent pathophysiological insights and therapeutic prospects , 2019, Journal of inherited metabolic disease.

[6]  D. Martinelli,et al.  Chronic liver involvement in urea cycle disorders , 2019, Journal of inherited metabolic disease.

[7]  N. Brunetti‐Pierri,et al.  Progress and challenges in development of new therapies for urea cycle disorders. , 2019, Human molecular genetics.

[8]  V. Rubio,et al.  Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision , 2019, Journal of inherited metabolic disease.

[9]  P. Codogno,et al.  Autophagy in liver diseases: Time for translation? , 2019, Journal of hepatology.

[10]  W. S. Denney,et al.  An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans , 2019, Science Translational Medicine.

[11]  D. Rubinsztein,et al.  Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation , 2018, Cell Death & Differentiation.

[12]  J. Minei,et al.  Beclin-1-Dependent Autophagy Protects the Heart During Sepsis , 2018, Circulation.

[13]  James M. Wilson,et al.  Adeno-associated viral gene therapy corrects a mouse model of argininosuccinic aciduria. , 2018, Molecular genetics and metabolism.

[14]  A. Rahim,et al.  Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer , 2018, Nature Communications.

[15]  D. Klionsky,et al.  AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc – Activity , 2018, Current Biology.

[16]  Ping Zhang,et al.  Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. , 2018, American journal of human genetics.

[17]  N. Brunetti‐Pierri,et al.  Targeting autophagy for therapy of hyperammonemia , 2018, Autophagy.

[18]  Joshua A Bittker,et al.  High-Throughput Screens To Identify Autophagy Inducers That Function by Disrupting Beclin 1/Bcl-2 Binding. , 2018, ACS chemical biology.

[19]  G. Bhagat,et al.  Disruption of the beclin 1/Bcl-2 autophagy regulatory complex promotes longevity in mice , 2018, Nature.

[20]  S. Vega-Rubín-de-Celis,et al.  Increased autophagy blocks HER2-mediated breast tumorigenesis , 2018, Proceedings of the National Academy of Sciences.

[21]  M. Prieve,et al.  Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  J. Shearer,et al.  The dynamic life of the glycogen granule , 2018, The Journal of Biological Chemistry.

[23]  A. Ballabio,et al.  Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia , 2017, Proceedings of the National Academy of Sciences.

[24]  H. Blasco,et al.  Liver involvement in urea cycle disorders: a review of the literature , 2017, Journal of Inherited Metabolic Disease.

[25]  A. Ballabio,et al.  mTORC1 hyperactivation arrests bone growth in lysosomal storage disorders by suppressing autophagy. , 2017, The Journal of clinical investigation.

[26]  Weiran Zhang,et al.  A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease , 2017, PLoS genetics.

[27]  Joshua A. Kritzer,et al.  Diversity-Oriented Stapling Yields Intrinsically Cell-Penetrant Inducers of Autophagy , 2017, Journal of the American Chemical Society.

[28]  H. Morizono,et al.  AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. , 2017, Molecular genetics and metabolism.

[29]  S. Cederbaum,et al.  Biopsy-proven Hepatocellular Carcinoma in a 53-year-old Woman With Arginase Deficiency , 2017, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[30]  R. Lachmann,et al.  Expanding the phenotype in argininosuccinic aciduria: need for new therapies , 2017, Journal of Inherited Metabolic Disease.

[31]  C. Chu,et al.  Autophagy induction stabilizes microtubules and promotes axon regeneration after spinal cord injury , 2016, Proceedings of the National Academy of Sciences.

[32]  F. Di Virgilio,et al.  Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. , 2016, Cancer cell.

[33]  Yang Yang,et al.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.

[34]  B. Bay,et al.  Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency. , 2016, Journal of hepatology.

[35]  Rosa Bartolomeo,et al.  FGF signalling regulates bone growth through autophagy , 2015, Nature.

[36]  S Shoji-Kawata,et al.  [Identification of a candidate therapeutic autophagy-inducing peptide]. , 2015, Seikagaku. The Journal of Japanese Biochemical Society.

[37]  J. Debnath,et al.  Autophagy at the crossroads of catabolism and anabolism , 2015, Nature Reviews Molecular Cell Biology.

[38]  Chang S. Chan,et al.  Autophagy is required for glucose homeostasis and lung tumor maintenance. , 2014, Cancer discovery.

[39]  Sang Gyun Kim,et al.  Rapamycin: one drug, many effects. , 2014, Cell metabolism.

[40]  J. Martina,et al.  The Nutrient-Responsive Transcription Factor TFE3 Promotes Autophagy, Lysosomal Biogenesis, and Clearance of Cellular Debris , 2014, Science Signaling.

[41]  Nina Raben,et al.  Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease , 2013, EMBO molecular medicine.

[42]  N. Brunetti‐Pierri,et al.  Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. , 2012, American journal of human genetics.

[43]  James M. Wilson,et al.  Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. , 2012, Molecular genetics and metabolism.

[44]  Marshall Summar,et al.  Requirement of argininosuccinate lyase for systemic nitric oxide production , 2011, Nature Medicine.

[45]  K. Klinger,et al.  Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. , 2010, Molecular genetics and metabolism.

[46]  Jae U. Jung,et al.  Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking , 2008, Nature Cell Biology.

[47]  A. Hamosh,et al.  Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. , 2007, The New England journal of medicine.

[48]  H. Morizono,et al.  Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  Keiko Kobayashi,et al.  Progressive Liver Fibrosis in Late-onset Argininosuccinate Lyase Deficiency , 2002, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[50]  K. Badizadegan,et al.  Focal glycogenosis of the liver in disorders of ureagenesis: Its occurrence and diagnostic significance , 1997, Hepatology.

[51]  E. Furth,et al.  Prolonged Metabolic Correction in Adult Ornithine Transcarbamylase-deficient Mice with Adenoviral Vectors (*) , 1996, The Journal of Biological Chemistry.

[52]  R. Demars,et al.  Abnormal ornithine carbamoyltransferase in mice having the sparse-fur mutation. , 1976, Proceedings of the National Academy of Sciences of the United States of America.